Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | GLA | P06280 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10943835 | 0.83 | ELANE (0.50) | ALOX15KMT2AKDM4ELMNARECQL | |
| SCHEMBL10944602 | 0.81 | CA12 (0.41) | ALOX15GAAKDM4EGLAHPGD | |
| SCHEMBL125575 | 0.81 | ALOX15 (0.41) | ALOX15KMT2AFGFR1TRPA1ELANE | |
| SCHEMBL28841758 | 0.81 | ALOX15 (0.44) | ALOX15KMT2AGAAKDM4EGLA | |
| SCHEMBL128069 | 0.78 | ELANE (0.40) | HSD17B10LMNAMAPK1TRPA1ELANE | |
| SCHEMBL11255665 | 0.76 | USP2 (0.45) | KMT2AGAAKDM4EHPGDHSD17B10 | |
| SCHEMBL124897 | 0.76 | ELANE (0.43) | TRPA1ELANEALDH1A1CYP3A4 | |
| SCHEMBL12655555 | 0.76 | KMT2A (0.52) | ALOX15KMT2AGAAKDM4EGLA | |
| SCHEMBL3517259 | 0.72 | — | — | |
| SCHEMBL3026330 | 0.72 | KMT2A (0.43) | ALOX15KMT2AGAAKDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2428577-B1 | Preparation of tyrosinase-inhibiting hydroxybenzyl and hydroxypyranonemethyl esters | EASTMAN CHEM CO (US) | 2014-01-22 | — | — | EP | disclosed |
| EP-2428577-A1 | Preparation of tyrosinase-inhibiting hydroxybenzyl and hydroxypyranonemethyl esters | EASTMAN CHEMICAL COMPANY (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2155886-B1 | Cosmetic use of inhibitors of tyrosinase | EASTMAN CHEM CO (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20110129430-A1 | HYDROXYBENZYL OR HYDROXYPYRANONEMETHYL ESTERS AS TYROSINASE INHIBITORS | EASTMAN CHEMICAL COMPANY (US) | 2011-06-02 | — | — | US | disclosed |
| US-20080306144-A1 | Hydroxybenzyl or hydroxypyranonemethyl esters as tyrosinase inhibitors | EASTMAN CHEMICAL COMPANY | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306144-A1 | Hydroxybenzyl or hydroxypyranonemethyl esters as tyrosinase inhibitors | TYR, TH, HAAO | ALOX15 1480/4885KMT2A 2193/4885GAA 25/4885 |
| US-20110129430-A1 | HYDROXYBENZYL OR HYDROXYPYRANONEMETHYL ESTERS AS TYROSINASE INHIBITORS | TYR, TH, HAAO | ALOX15 1480/4885KMT2A 2193/4885GAA 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.